In historic FDA nod, AstraZeneca, Daiichi’s Enhertu snags ultrafast approval in broad HER2-low breast cancer use – FiercePharma

In historic FDA nod, AstraZeneca, Daiichi’s Enhertu snags ultrafast approval in broad HER2-low breast cancer use – FiercePharma
Source: Google NewsPublished on 2022-08-05